Drug interaction evaluation of the novel phosphodiesterase type 5 inhibitor tunodafil (youkenafil): Effects of tunodafil on omeprazole pharmacokinetics based on CYP2C19 gene polymorphism, and effects of ritonavir on tunodafil pharmacokinetics

• Published in: European journal of pharmaceutical sciences Vol. 206; p. 107010
• Main Authors: Wang, Keli, Ding, Juefang, Cheng, Minlu, Li, Xianjing, Zhou, Huan, Song, Qinxin, Yang, Yuanxun, Li, Juan, Ding, Li
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.03.2025
• Subjects: Adult; CYP2C19 polymorphism; Cytochrome P-450 CYP2C19 - genetics; Cytochrome P-450 CYP2C19 - metabolism; Cytochrome P-450 CYP2C19 Inhibitors - pharmacology; Drug Interactions; Drug-drug interaction; Female; Humans; Imidazoles - pharmacokinetics; Imidazoles - pharmacology; Male; Microsomes, Liver - drug effects; Microsomes, Liver - metabolism; Middle Aged; Omeprazole; Omeprazole - blood; Omeprazole - pharmacokinetics; Pharmacokinetics; Phosphodiesterase 5 Inhibitors - pharmacokinetics; Phosphodiesterase 5 Inhibitors - pharmacology; Polymorphism, Genetic; Ritonavir; Ritonavir - pharmacology; Tunodafil (youkenafil); Young Adult; Omeprazole; CYP2C19 polymorphism; Drug-drug interaction; Pharmacokinetics; Ritonavir; Tunodafil (youkenafil)

•Tunodafil exhibits moderate inhibitory effects on CYP2C19 and CYP3A4/5 in vitro.•Tunodafil inhibits different CYP2C19 genotypes to different degrees in vivo.•Ritonavir has clinically significant drug interactions with tunodafil. To evaluate the drug-drug interactions (DDI) of tunodafil (youkenafil)...